Peter W Eide

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5208271/publications.pdf Version: 2024-02-01



DETED W/ FIDE

#	Article	IF	CITATIONS
1	Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies. Molecular Cancer, 2017, 16, 116.	19.2	232
2	CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models. Scientific Reports, 2017, 7, 16618.	3.3	229
3	Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies. Clinical Cancer Research, 2018, 24, 794-806.	7.0	177
4	MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer. Oncotarget, 2016, 7, 6476-6505.	1.8	93
5	Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity. Clinical Cancer Research, 2020, 26, 4107-4119.	7.0	68
6	NEDD4 is overexpressed in colorectal cancer and promotes colonic cell growth independently of the PI3K/PTEN/AKT pathway. Cellular Signalling, 2013, 25, 12-18.	3.6	65
7	Prognostic, predictive, and pharmacogenomic assessments of <scp>CDX</scp> 2 refine stratification of colorectal cancer. Molecular Oncology, 2018, 12, 1639-1655.	4.6	40
8	Long noncoding RNA <i>MIR31HG</i> is a <i>bona fide</i> prognostic marker with colorectal cancer cellâ€intrinsic properties. International Journal of Cancer, 2019, 144, 2843-2853.	5.1	33
9	Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer. Npj Genomic Medicine, 2021, 6, 59.	3.8	29
10	Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity. EBioMedicine, 2020, 59, 102923.	6.1	22
11	Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer. Oncogenesis, 2019, 8, 35.	4.9	19
12	E3 ubiquitin ligase NEDD4 induces endocytosis and lysosomal sorting of connexin43 to promote loss of gap junctions. Journal of Cell Science, 2017, 130, 2867-2882.	2.0	14
13	Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer. ESMO Open, 2019, 4, e000523.	4.5	11
14	De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity. Genome Medicine, 2021, 13, 143.	8.2	10
15	Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases. Journal of Translational Medicine, 2021, 19, 384.	4.4	6
16	The expressed mutational landscape of microsatellite stable colorectal cancers. Genome Medicine, 2021, 13, 142.	8.2	4
17	Eâ€cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models. Molecular Oncology, 2022, 16, 2312-2329.	4.6	4